HC Wainwright reaffirmed their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV – Free Report) in a report issued on Tuesday, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock.
Enlivex Therapeutics Stock Up 3.9 %
Shares of ENLV stock opened at $1.32 on Tuesday. The firm has a 50 day moving average price of $3.26 and a two-hundred day moving average price of $2.54. The company has a market capitalization of $24.51 million, a PE ratio of -0.85 and a beta of 1.02. Enlivex Therapeutics has a 12-month low of $1.15 and a 12-month high of $4.59.
Enlivex Therapeutics Company Profile
Read More
- Five stocks we like better than Enlivex Therapeutics
- Breakout Stocks: What They Are and How to Identify Them
- Charles Schwab Fortifies its Uptrend on EPS Beat
- P/E Ratio Calculation: How to Assess Stocks
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.